Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 22;9(3):00034-2023.
doi: 10.1183/23120541.00034-2023. eCollection 2023 May.

ERS International Congress 2022: highlights from the Airway Diseases Assembly

Augusta Beech  1   2 , Andrea Portacci  3 , Beatrice Herrero-Cortina  4   5 , Alexander G Mathioudakis  6 , Carolina Gotera  7 , Lena Uller  8 , Fabio Luigi Massimo Ricciardolo  9   10 , Pavol Pobeha  11 , Robert J Snelgrove  12 , Gert-Jan Braunstahl  13 , Apostolos Bossios  14   15 , Omar Usmani  12 , Sachin Ananth  16
Affiliations
Review

ERS International Congress 2022: highlights from the Airway Diseases Assembly

Augusta Beech et al. ERJ Open Res. .

Abstract

The European Respiratory Society (ERS) celebrated the return of an in-person meeting in Barcelona, Spain, after 2 years of virtual congresses. The ERS Congress 2022 programme was replete with symposia, skills workshops and abstract presentations from all 14 assemblies, encompassing over 3000 abstracts presented in the form of thematic poster discussion and oral presentations. In this article, highlights from the ERS Congress 2022 (including from thematic poster sessions, oral presentations and symposia from keynote speakers), presented by Assembly 5 (Airway diseases, asthma, COPD and chronic cough), are reviewed by Early Career Members and experts in the field, with the aim of presenting key recent findings in the field.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A. Portacci declares honoraria from AstraZeneca, GlaxoSmithKline, Chiesi and Sanofi. C. Gotera declares payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca and GlaxoSmithKline. L. Uller reports payment or honoraria from AstraZeneca for lectures, presentations, speakers’ bureaus, manuscript writing or educational events. P. Pobeha declares payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca and Angeliny, is secretary of Group 05.02 (monitoring airway disease) of the European Respiratory Society, and a member of steering committees of the Slovak respiratory society and Slovak sleep medicine society. R.J. Snelgrove declares grants from The Wellcome Trust. G-J. Braunstahl reports attending advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Boehringer Ingelheim and Sanofi, honoraria from Novartis, AstraZeneca, Chiesi, GlaxoSmithKline, Teva and ALK Abello, participating in research with GlaxoSmithKline, Chiesi, AstraZeneca, ALK Abello, Novartis and Teva, and attending international conferences with Novartis and Teva. A. Bossios declares honoraria for advisory board meetings from GSK, AstraZeneca, Teva, Novartis and Sanofi, is a member of the steering committee of SHARP, secretary of Assembly 5 (airway diseases, asthma, COPD and chronic cough) of the European Respiratory Society and vice-chair of the Nordic Severe Asthma Network. O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline, personal fees from Napp, Mundipharma, from Sandoz and Takeda, grants from Edmond Pharma, and personal fees from Cipla, Covis, Novartis, Mereo Biopharma, Orion, Menarini, UCB, Trudell Medical, Deva, Kamada, Covis and Kyorin, outside the submitted work; and is chair of Assembly 5 (airway diseases, asthma, COPD and chronic cough) of the European Respiratory Society. A. Beech, F.L.M. Ricciardolo, B. Herrero-Cortina, A.G. Mathioudakis and S. Ananth declare no conflicts of interest.

References

    1. Agusti A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med 2019; 381: 1248–1256. doi:10.1056/NEJMra1900475 - DOI - PubMed
    1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645–1648. doi:10.1136/bmj.1.6077.1645 - DOI - PMC - PubMed
    1. Stolz D, Mkorombindo T, Schumann DM, et al. . Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 2022; 400: 921–972. doi:10.1016/S0140-6736(22)01273-9 - DOI - PMC - PubMed
    1. Martinez FJ, Agusti A, Celli BR, et al. . Treatment trials in young patients with chronic obstructive pulmonary disease and pre-chronic obstructive pulmonary disease patients: time to move forward. Am J Respir Crit Care Med 2022; 205: 275–287. doi:10.1164/rccm.202107-1663SO - DOI - PMC - PubMed
    1. Veneroni C, Valach C, Wouters E, et al. . Diagnostic potential of forced oscillometry technique in adults with normal spirometry: data from the LEAD general population cohort. Eur Respir J 2022; 60: Suppl. 66, 4465.